pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Treatment response of vitamin K antagonists (VKAs) according to
| Study | Note | Type of VKAs | Response of VKAs | |||||
|---|---|---|---|---|---|---|---|---|
| TT type | CT type | CC type | ||||||
| de Oliveira Almeida VC et al. 2014 | Resistance rate n (%) | Warfarin | 16 (29.6) | - | - | |||
| Ferrari M et al. 2014 | TTR >85% TTR <55% n (%) |
Warfarin | 4 (28.6) 10 (71.4) |
21 (51.2) 20 (48.8) |
8 (72.7) 3 (27.3) |
|||
| Gschwind L et al. 2015 | Hazard ratio for time-to-achieve stability (95% CI) | Acenocoumarol | 2.81 (1.18-6.67) |
1.12 (0.49-2.55) | 1 |
|||
| Rojo M et al. 2020 | TTR (days), n | Acenocoumarol | 244 [305], 107 | 240 [299], 135 | 203 [201], 37 | |||
| Study | Note | Type of VKAs | Incidence rate of bleeding events | |||||
| TT type, n (%) | CT type, n (%) | CC type, n (%) | ||||||
| Yes | No | Yes | No | Yes | No | |||
| Wadelius M et al. 2004 | - | Warfarin | 11 (14.3) | 66 (85.7) | 21 (18.4) | 93 (81.6) | 4 (11.8) | 30 (88.2) |
| Sychev DA et al. 2016 | - | Acenocoumarol | 6 (40) |
9 (60) | 13 (52) |
12 (48) | 1 (10) |
9 (90) |
*